Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The Phase I portion of the study is to assess the maximum tolerated dose of vorinostat when
combined with carboplatin plus etoposide. The Phase II portion is to determine
progression-free survival among patients with extensive disease small cell lung cancer
receiving carboplatin plus etoposide with vorinostat.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Collaborators:
Merck Sharp & Dohme Corp. University of Pennsylvania